An experimental drug candidate developed at the University of Michigan reversed a severe form of fatty liver disease in animal studies by acting on the gut, according to research published in The Journal of Clinical Investigation.
The compound, DT-109, was reported to reduce harmful gut bacteria, reinforce the intestinal lining and limit the passage of inflammatory microbial products into the body. In animal models, that combination reversed metabolic dysfunction-associated steatohepatitis, or MASH.
A difficult liver disease
MASH is a serious form of fatty liver disease in which fat builds up in the liver alongside inflammation and cellular damage. The disease can progress to cirrhosis, liver cancer and liver failure. The supplied report estimates that MASH affects about 7% of the global population and notes that effective treatment options remain limited despite recent advances.
The new research focuses on an important connection between the intestine and the liver. When the intestinal barrier is impaired, microbial products from the gut can enter circulation and contribute to inflammation and disease progression elsewhere in the body, including the liver.
How DT-109 is intended to work
DT-109 is a glycine-based tripeptide, a small molecule made from three amino acids. The Michigan team had previously found that it could improve MASH in animal studies. The newer work examined the mechanism behind that effect.
The researchers found evidence that the compound protected the gut’s epithelial barrier and reduced the systemic influx of harmful microbial products. The source report says DT-109 also reduced harmful gut bacteria, connecting changes in the microbiome and intestinal barrier with improvements in liver disease.
That makes the study notable because it does not treat the liver as an isolated organ. Instead, it suggests that repairing upstream dysfunction in the gut may reduce an inflammatory pressure that drives liver injury.
Animal evidence, not a clinical result
The results are promising but preliminary. They come from animal studies, and the supplied source does not describe evidence from human clinical trials. A drug that improves MASH in an animal model must still be evaluated for safety, dosing, durability and effectiveness in people.
The research also does not establish that every person with MASH would have the same gut-related disease mechanism or respond to the same treatment. MASH can develop through multiple, interacting metabolic and inflammatory pathways.
Why the gut-liver route matters
If the approach holds up in further research, it could broaden how scientists think about treating fatty liver disease. Rather than focusing only on processes inside the liver, treatment might address the intestinal barrier and microbial signals that can reach it.
The work is also a reminder that drug development for chronic metabolic disease may depend on intervening across organ systems. For DT-109, the next key question is whether the gut-protective effect can translate into a safe, meaningful clinical benefit for patients with MASH.
This article is based on reporting by Science Daily. Read the original article.
Originally published on sciencedaily.com
